A pharmaceutical composition and preparation method thereof

Through the method of sulfate polysaccharide coating small molecule active substances, the problem of insufficient stability and dispersion of small molecule active substances in the organisms is solved, the bioavailability and sustained release effect are improved, and the research and development of new drugs is promoted.

CN115120734BActive Publication Date: 2024-11-01JIMEI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210571464.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-24
Publication Date
2024-11-01
Estimated Expiration
2042-05-24

AI Technical Summary

Technical Problem

Due to its small molecular weight, poor metabolism in the body, and low blood drug concentration after medication, small molecule active substances limit their research and development and application as clinical drugs. It is necessary to improve their stability and dispersion in the organisms, enhance the sustained release effect of drugs, and improve the Bioavailability.

Method used

The pharmaceutical composition that uses sulfate polysaccharides to coat small-molecular active substances can enhance their biological activity through the synergistic effect of red algae sulfate polysaccharides with small-molecular active substances such as berberine, baicalin, etc., and nanoparticles are formed through molecular self-assembly. Improve its stability and dispersion.

Benefits of technology

The sulfate polysaccharide coated with small molecule active substances has significantly improved its bioavailability and sustained release effect, enhanced the biological function of the drug, and promoted the research and development and application of new small molecule drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003660424840000051
    Figure BDA0003660424840000051
  • Figure HDA0003660424850000011
    Figure HDA0003660424850000011
  • Figure HDA0003660424850000021
    Figure HDA0003660424850000021
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition, which comprises a sulfated polysaccharide and a small molecule active substance, wherein the sulfated polysaccharide encapsulates the small molecule active substance. The composition can make the sulfated polysaccharide and the small molecule active substance produce a synergistic effect, enhance their biological activity, and provide support for the research and development and application of new small molecule drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug synthesis, and in particular to a drug composition of a sulfated polysaccharide coated small molecule active substance and a preparation method thereof. Background Art

[0002] Small molecule drugs have the advantages of clear structure, clear target, and easy synthesis and production. Many studies have found that small molecule active substances from traditional Chinese medicine or food have physiological functions such as anti-infection, anti-virus, and anti-allergy. For example, baicalin, berberine, curcumin, quercetin, etc. are all good natural active ingredients, but due to factors such as small molecular weight, poor metabolism in the body, and low blood drug concentration after medication, their research and development as clinical drugs are limited.

[0003] Therefore, improving the stability and dispersibility of small molecule active substances in the body, enhancing their sustained-release effects, and improving bioavailability are of great significance to promoting the development and application of new small molecule drugs. Summary of the invention

[0004] The purpose of the present invention is to provide a pharmaceutical composition and a preparation method thereof, wherein the pharmaceutical composition is a small molecule active substance coated with sulfated polysaccharide, and the composition can make the sulfated polysaccharide and the small molecule active substance produce a synergistic effect, enhance their biological activity, and provide support for the research and development and application of new small molecule drugs.

[0005] To achieve this object, the present invention adopts the following technical solutions:

[0006] According to a first aspect of the present invention, a pharmaceutical composition is provided, comprising a sulfated polysaccharide and a small molecule active substance, wherein the sulfated polysaccharide encapsulates the small molecule active substance.

[0007] According to some embodiments of the present invention, the sulfated polysaccharide is a red algae sulfated polysaccharide; preferably, the red algae is selected from Pyrophyta haitanensis, Gracilaria lemaneiformis and Eucheuma indica.

[0008] According to some embodiments of the present invention, the small molecule active substance is selected from a complex of berberine or a salt thereof and baicalin, berberine or a salt thereof, baicalin, curcumin, quercetin and secondary metabolites of microorganisms.

[0009] According to some embodiments of the present invention, the small molecule active substance is a complex of berberine and baicalin.

[0010] According to a preferred embodiment of the present invention, the small molecule active substance is a nanoparticle formed by isoquinoline alkaloids and flavonoid glycosides. Preferably, the small molecule active substance is a nanoparticle formed by isoquinoline alkaloids and flavonoid glycosides through molecular self-assembly. Molecular self-assembly is a type of stable molecular aggregate or supramolecular structure with certain specific functions or properties formed by non-covalent bond interactions or spontaneous combinations between molecules under equilibrium conditions.

[0011] According to some embodiments of the present invention, the ultraviolet spectrum of the complex of berberine and baicalin has one maximum absorption peak at wavelengths of 315nm-345nm and 263nm-275nm respectively.

[0012] According to some embodiments of the present invention, the complex of berberine and baicalin is obtained by the following method:

[0013] (1) dissolving berberine and baicalin in water respectively, and adjusting the pH of the baicalin aqueous solution to 6-12, preferably 8-12;

[0014] (2) The berberine aqueous solution and the baicalin aqueous solution are mixed, heated and stirred, and centrifuged to obtain a precipitate which is a complex of berberine and baicalin.

[0015] According to some embodiments of the present invention, the molar ratio of berberine to baicalin is 1:(0.1-10), for example 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10.

[0016] According to a preferred embodiment of the present invention, an organic base or an inorganic base is used to adjust the pH of the baicalin aqueous solution to 8-12. Preferably, the inorganic base is selected from sodium hydroxide, sodium bicarbonate and sodium carbonate.

[0017] According to some embodiments of the invention, the berberine aqueous solution and the baicalin aqueous solution are mixed in a volume ratio of 1:(0.1-10), for example, 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10.

[0018] According to some embodiments of the present invention, the heating temperature is 30°C-100°C, such as 30°C, 50°C, 80°C, 100°C, preferably 60°C-90°C.

[0019] According to some embodiments of the present invention, the stirring is magnetic stirring, and the time of the magnetic stirring is 20min-80min, for example 30min, 40min, 50min, 60min, 70min, 80min, preferably 40min-70min; the rotation speed of the magnetic stirring is 10-20, for example 10, 15, 20.

[0020] According to some embodiments of the present invention, the centrifugal rotation speed is 4000rpm-10000rpm, for example 4000rpm, 5000rpm, 6000rpm, 7000rpm, 8000rpm, 9000rpm, 10000rpm, preferably 7000rpm-9000rpm.

[0021] According to some embodiments of the present invention, the precipitate obtained by centrifugation is washed with ultrapure water to obtain the complex of berberine and baicalin.

[0022] According to some embodiments of the present invention, the small molecule active substance is a complex of berberine hydrochloride and baicalin.

[0023] According to some embodiments of the present invention, the small molecule active substance is a secondary metabolite of a microorganism.

[0024] According to a preferred embodiment of the present invention, the small molecule active substance has a nanostructure.

[0025] According to a preferred embodiment of the present invention, the small molecule active substance is nanoparticles, nanorods or nanofibers.

[0026] According to a preferred embodiment of the present invention, the small molecule active substance has a nanofiber structure, the diameter of the nanofiber is 1nm-50nm, each nanofiber is connected by a bead-like structure composed of small nanoparticles, and the nanofibers are interwoven to form a mesh structure.

[0027] According to some embodiments of the present invention, the monosaccharides of the sulfated polysaccharide are mainly D-galactose and L-galactose, the sulfate mass content of the sulfated polysaccharide is 10% to 30%, and the average molecular weight of the sulfated polysaccharide is 500 to 3000 kDa.

[0028] According to a second aspect of the present invention, there is provided a method for preparing the composition, comprising the steps of:

[0029] mixing the sulfated polysaccharide with the first solvent to form a sulfated polysaccharide solution;

[0030] mixing the small molecule active substance with the second solvent to form a small molecule active substance solution;

[0031] The sulfated polysaccharide solution is mixed with the small molecule active substance solution.

[0032] According to some embodiments of the present invention, the first solvent is ultrapure water.

[0033] According to some embodiments of the present invention, the second solvent is ultrapure water.

[0034] According to some embodiments of the present invention, the concentration of the sulfated polysaccharide solution is 3 mg / mL-15 mg / mL, preferably 5 mg / mL-10 mg / mL.

[0035] According to some embodiments of the present invention, the concentration of the small molecule active substance solution is 0.2 mmol / L-10 mmol / L, preferably 0.5 mmol / L-5 mmol / L, and more preferably 2 mmol / L-4 mmol / L.

[0036] According to some embodiments of the present invention, the volume ratio of the sulfated polysaccharide solution and the small molecule active substance solution is (1-3):1.

[0037] According to some embodiments of the present invention, the sulfated polysaccharide is prepared by the following method:

[0038] (1) mixing algae dry powder and solvent A at a solid-liquid ratio of 1:(50-90) to obtain a mixed solution;

[0039] (2) freezing the obtained mixed solution and then thawing it to obtain a thawed mixed solution;

[0040] (3) Adding solvent B to the thawed mixed solution, the resulting precipitate is sulfated polysaccharide.

[0041] According to some embodiments of the present invention, the mixed solution obtained in step (2) is frozen and then thawed, and the freezing and thawing operations are repeated 3 to 6 times to obtain a thawed mixed solution.

[0042] According to some embodiments of the present invention, the solvent A is ultrapure water.

[0043] According to some embodiments of the invention, the solvent B is ethanol.

[0044] According to some embodiments of the present invention, the freezing temperature is -30°C to -18°C.

[0045] According to some embodiments of the present invention, the thawing temperature is 50°C to 60°C.

[0046] According to a third aspect of the present invention, there is provided a use of a sulfated polysaccharide in drug preparation, wherein the sulfated polysaccharide is used as a coating material for the drug.

[0047] According to some embodiments of the present invention, the drug is a small molecule drug.

[0048] Compared with the prior art, the present invention has the following advantages: 1. The sulfated polysaccharide used in the present invention has the advantages of abundant sources, low cost, high biocompatibility, safety and non-toxicity, etc., and can stabilize and disperse small molecule active substances well through coating, so that they can play good biological functions; 2. The composition provided by the present invention can enhance the sustained release effect of drugs including small molecule active substances such as berberine and baicalin, improve their bioavailability, and facilitate the research and development of new small molecule drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 The infrared spectra of the three red algae sulfated polysaccharides obtained in Example 1 are shown, (A) is the infrared spectra of PHSP, (B) is the infrared spectra of ESP, and (C) is the infrared spectra of GLSP.

[0050] Figure 2 Photographs of BBR-BA-PHSP and BBR-BA-ESP obtained in Example 2 are shown, (A) BBR-BA-PHSP, (B) BBR-BA-ESP.

[0051] Figure 3 The scanning electron micrographs of BBR-BA-PHSP and BBR-BA-ESP obtained in Example 2 are shown, (A) BBR-BA-PHSP, (B) BBR-BA-ESP.

[0052] Figure 4 The scanning electron microscope image of BBR-BA obtained in Example 2 is shown.

[0053] Figure 5 The results of the inhibition rate of RBL-2H3 degranulation by different concentrations of BBR-BA, BBR-BA-PHSP and BBR-BA-ESP are shown.

[0054] Figure 6 The C obtained in Example 3 is shown 1+2 -SEM image of PHSP. DETAILED DESCRIPTION

[0055] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation to the present invention.

[0056] definition

[0057] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs.

[0058] The term "small molecule active substances" used in this article refers to compounds or complexes with a molecular weight of less than 1000 Daltons, including small peptides, oligopeptides, oligosaccharides, oligonucleotides, vitamins, minerals, plant secondary metabolites and their degradation products, such as aglycones, flavonoids, aglycones, alkaloids, etc. with biological activity.

[0059] The term "nanostructure" used in this article refers to a tiny structure with a size of less than 100nm. It is a new system constructed or assembled according to certain rules based on nanoscale material units. It includes one-dimensional, two-dimensional, and three-dimensional systems. These material units include nanoparticles, stable clusters or artificial superatoms, nanotubes, nanorods, nanowires, nanowires, and nano-sized holes.

[0060] Example 1 Preparation and property analysis of red algae sulfated polysaccharide

[0061] Three kinds of red algae (Porphyra hainanensis, Eucheuma truncatula and Gracilaria lemaneiformis) were washed, dried and crushed into dry powder respectively, and the three kinds of red algae dry powder were mixed with ultrapure water in a solid-liquid ratio of 1:90, frozen at -18°C for 4 hours, thawed at 55°C, and frozen and thawed repeatedly for 4 times, and then precipitated with ethanol overnight. After re-dissolving on the next day, they were vacuum freeze-dried to obtain the three kinds of red algae sulfated polysaccharides.

[0062] The total sugar, reducing sugar, sulfate, endotoxin content, average molecular weight and viscosity of the three red algae sulfated polysaccharides were tested. The results are shown in Table 1.

[0063] Table 1 Properties of red algae sulfated polysaccharides

[0064]

[0065] The structures and functional groups of the three prepared red algae sulfated polysaccharides were analyzed by Fourier transform infrared spectroscopy. Figure 1 shown. Figure 1 A is the infrared spectrum of PHSP, PHSP at 3350cm -1 There is an absorption peak at 2935cm -1 There is a peak at 1400cm, indicating the antisymmetric stretching vibration of methylene; -1 -1200cm -1 The CH bending and stretching vibration peak appears at 1015cm -1 The strong characteristic absorption peak of CO appears at 1216 cm -1 and 767cm -1 There is a characteristic absorption peak of sulfate.

[0066] Figure 1 B is the infrared spectrum of ESP, ESP in the characteristic spectral band area 3450cm-1 is the stretching vibration of OH, 2923 cm -1 The stretching vibration of CH is the characteristic absorption of polysaccharides, 1641 cm -1 It is the characteristic absorption of C=O, in the fingerprint region 1249cm -1 The stretching vibration of O=S=O indicates that the polysaccharide contains sulfate groups. -1 The characteristic absorption at 929 cm indicates the presence of galactopyranose in the main chain. -1 Characteristic absorption of 3,6-internal ether galactose residue on CO; 846 cm -1 CO-SO on C4 of pyranose ring 3 The characteristic absorption of the hemiacetal hydroxyl group of the glycoside is α-configuration, 804cm -1 CO-SO on C2 of pyranose ring 3 This is similar to the characteristic spectrum of ι-carrageenan.

[0067] Figure 1 C is the infrared spectrum of GLSP. The characteristic absorption peaks of GLSP are: 3289cm -1 It is the stretching vibration of OH hydrogen bonds within or between molecules; 2920cm -1 Antisymmetric stretching vibration of methylene; 1400cm -1 ~1200cm -1 The left and right absorption peaks are the bending vibration absorption peaks of CH; 1070cm -1 The absorption peak is the OH bending vibration; at 1260cm -1 and 850cm -1 There is an obvious absorption peak of sulfate group at 931cm -1 The characteristic absorption peak appearing at indicates that the polysaccharide contains 3,6-ether galactose.

[0068] Example 2 Berberine / baicalin complex nanoparticles coated with red algae sulfate polysaccharide

[0069] (1) Prepare aqueous solutions of berberine (BBR) and baicalin (BA), each with a concentration of 2 mM.

[0070] (2) A round-bottom flask with 8.51 mL BA (2 mM pH 10.0) and 8.51 mL BBR (2 mM) added was placed on a heat-collecting constant temperature magnetic stirrer (80°C) at a speed of 20 rpm. The mixture was heated and stirred for 1 h. After centrifugation at 9000 r / min, the supernatant was discarded. The precipitate after centrifugation was the berberine / baicalin nanocomplex, named BBR-BA. The precipitate was washed three times with ultrapure water, and 4.25 mL ultrapure water was added and mixed to obtain a nanoparticle aqueous solution of the berberine / baicalin complex.

[0071] (3) The red algae sulfated polysaccharide (PHSP or ESP) was dissolved in ultrapure water to prepare a viscous solution with a concentration of 5 mg / mL, and mixed with an aqueous solution of nanoparticles of berberine / baicalin complex at a volume ratio of 1:1 to obtain a uniform nanoparticle aqueous solution of BBR-BA-PHSP or BBR-BA-ESP ( Figure 2 ).

[0072] (4) Drop the BBR-BA-PHSP or BBR-BA-ESP aqueous solution on the conductive resin, vacuum dry it, and then coat it with a gold film using a LEICA-EM-ACE600 sputtering coater. Use SEM (ZEISS-SUPRA55, Germany) to image at 10 kV to observe the morphology of the self-assembly. The results are as follows: Figure 3 As shown in the figure, BBR-BA-PHSP and BBR-BA-ESP are both irregular particles with uniform morphology. It can be seen that all particles are covered and gathered by a layer of paste-like substance, so the edge contour of the particles cannot be clearly observed under the electron microscope. In contrast, after drying, BBR-BA nanoparticles were observed under a scanning electron microscope to have a nanofiber structure. The diameter of the nanofiber is 1nm-50nm. Each nanofiber is connected by a bead-like structure composed of small nanoparticles. The nanofibers are interwoven to form a mesh structure ( Figure 4 ). It can be seen that the coating effect of sulfated polysaccharide can make the dispersibility of BBR-BA nanoparticles better.

[0073] (5) Antiallergic activity test of BBR-BA-PHSP and BBR-BA-ESP

[0074] RBL-2H3 cells were sensitized with anti-DNP-IgE (200 ng / mL) for 12 to 16 hours, and then activated with 500 ng / mL DNP-BSA for 1 hour. The cell culture supernatant and lysate were collected 1 hour later, and the release rate of β-hexosaminidase was detected to determine the activation of mast cells, thus constructing an IgE-mediated mast cell activation allergy model. The specific operation is as follows:

[0075] a. Use a 96-well cell culture plate and add 5×10 4 100 μL of RBL-2H3 cell suspension was added with anti-DNP-IgE at a final concentration of 200 ng / mL for sensitization overnight (16 h);

[0076] b. Wash the plate once with PBS (eight-row pipette) to remove unbound IgE, add 90 μL benchtop buffer and 5 μL sample (final concentrations of 5 μM, 10 μM, and 20 μM) to each well;

[0077] c. After 1 h of incubation, 5 μL DNP-BSA (final concentration 500 ng / mL) was added, PBS was added to the negative control wells, and DNP-BSA was added to the positive control wells;

[0078] d.1h later, the cell culture supernatant and lysate were collected, the degranulation efficiency of each well was determined, and the inhibition rate of the sample on RBL-2H3 degranulation was calculated (inhibition rate = (DNP-BSA group 脱颗粒效率 -Sample Group 脱颗粒效率 ) / (DNP-BSA group 脱颗粒效率 -PBS group 脱颗粒效率 )×100%);

[0079] e. The release rate of β-hexosaminidase is as follows Figure 5 As shown, compared with DNP-BSA, 5 μM and 10 μM BBR-BA were able to inhibit the activation of RBL-2H3 cells, and the anti-allergic activity was significantly improved after being wrapped with PHSP.

[0080] Example 3: Deep-sea derived small molecule nanoparticles coated with red algae sulfate polysaccharide

[0081] (1) Two secondary metabolites of deep-sea microorganisms (named C1 and C2) were selected, C1 and C2 were dissolved in ultrapure water, and they were mixed evenly by ultrasound to adjust the concentration to 500 μmol / L.

[0082] (2) The pH of the C2 solution was adjusted to 9.0, C1 and C2 were mixed in a ratio of 1:1, and then heated in a water bath at 80°C and magnetically stirred for 1 h using a heat collecting constant temperature magnetic stirrer. After cooling, a mixture of C1 and C2 was obtained. 1+2 .

[0083] (3) Dissolve red algae sulfated polysaccharide (PHSP) in ultrapure water to prepare a 5 mg / mL viscosity solution, and mix C 1+2 , to obtain a uniform nanoparticle aqueous solution C 1+2 -PHSP( Figure 6 ), the microstructure of the self-assembly was characterized by scanning electron microscopy. Under SEM, it was observed that the dried sample was a short rod-like structure with uniform morphology and uniform dispersion.

[0084] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. A pharmaceutical composition, comprising a sulfated polysaccharide and a small molecule active substance, wherein the sulfated polysaccharide encapsulates the small molecule active substance; The sulfated polysaccharide is Porphyra haitanensis sulfated polysaccharide; The small molecule active substance is selected from the complex of berberine or its salt and baicalin.

2. The pharmaceutical composition according to claim 1, It is characterized in that The small molecule active substance has a nanostructure.

3. The pharmaceutical composition according to claim 1 or 2, It is characterized in that The monosaccharides of the sulfated polysaccharide include D-galactose and L-galactose, the sulfate mass content of the sulfated polysaccharide is 10% to 30%, and the average molecular weight of the sulfated polysaccharide is 500 kDa to 3000 kDa.

4. A method for preparing the pharmaceutical composition according to any one of claims 1 to 3, comprising the following steps: mixing the sulfated polysaccharide with the first solvent to form a sulfated polysaccharide solution; mixing the small molecule active substance with a second solvent to form a small molecule active substance solution; The sulfated polysaccharide solution is mixed with the small molecule active substance solution.

5. The method according to claim 4, It is characterized in that The concentration of the sulfated polysaccharide solution is 3 mg / mL-15 mg / mL; the concentration of the small molecule active substance solution is 0.2 mmol / L-10 mmol / L.

6. The method according to claim 4 or 5, It is characterized in that The volume ratio of the sulfated polysaccharide solution to the small molecule active substance solution is (1-3):

1.

7. The method according to claim 4 or 5, It is characterized in that The sulfated polysaccharide is prepared by the following method: (1) Mixing algae dry powder and solvent A at a solid-liquid ratio of 1:(50-90) to obtain a mixed solution; (2) freezing the obtained mixed solution and then thawing it to obtain a thawed mixed solution; (3) Add solvent B to the thawed mixed solution, and the resulting precipitate is sulfated polysaccharide.

8. The method according to claim 7, It is characterized in that The freezing temperature is -30°C to -18°C, and / or the thawing temperature is 50°C to 60°C.